Published in JAMA Psychiatry, the study found that more than half of patients with binge eating disorder and one third of patients with atypical anorexia nervosa reported having used GLP-1 medications
Protecting patients and trust The dangers are abundantly clear: a poorly regulated peptide market awash with misinformation will set back progress in obesity medication by years and put people in danger
Even as their overall grocery spending drops by 6%, their produce purchases rise
Safety Concerns and Reported Complications There have been growing reports of adverse reactions associated with compounded semaglutide, including unexpected gastrointestinal side effects, excessive nausea, severe dehydration, and symptoms not typically seen with FDA-approved GLP-1 medications
Each person will respond to treatment differently and assess the balance of costs and benefits to their heath differently
"If anything, when we slow down the titration, we would expect the accountability to be even further improved," Chakravarthy told CNBC
%20(1).png)
